Since tumor hypoxia has been linked with poor prognosis in cancer patients30, we next examined the tumor expression of hypoxia indicator glucose transporter (Glut1) in all treatment groups, indicating that the HK2 inhibitor or HK2 inhibitor and doxorubicin combination treatment significantly reduced tumor hypoxia (Supplementary fig. 8s), suggesting that the improved blood vessel function reduced tumor hypoxia in mice treated with HK2 inhibitor. Here, HK2 is linked to neoplasm.